Becton, Dickinson and Company Share Price Swiss Exchange

Equities

BDX

US0758871091

Medical Equipment, Supplies & Distribution

Market Closed - Swiss Exchange 16:35:20 28/06/2019 BST 5-day change 1st Jan Change
243.4 CHF +0.72% Intraday chart for Becton, Dickinson and Company -.--% -.--%

Financials

Sales 2024 * 20.25B 18.13B 1,580B Sales 2025 * 21.47B 19.23B 1,675B Capitalization 66.14B 59.23B 5,160B
Net income 2024 * 2.09B 1.88B 163B Net income 2025 * 2.48B 2.22B 193B EV / Sales 2024 * 3.91 x
Net Debt 2024 * 13.13B 11.76B 1,024B Net Debt 2025 * 10.8B 9.67B 842B EV / Sales 2025 * 3.58 x
P/E ratio 2024 *
32.1 x
P/E ratio 2025 *
28.5 x
Employees -
Yield 2024 *
1.64%
Yield 2025 *
1.68%
Free-Float 77.74%
More Fundamentals * Assessed data
Dynamic Chart
Evercore ISI Adjusts Price Target on Becton, Dickinson to $285 From $290, Maintains Outperform Rating MT
BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool CI
Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024 CI
Evercore ISI Raises Becton, Dickinson and Company's Price Target to $290 From $282 MT
Sector Update: Health Care Stocks Steady Premarket Monday MT
Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash DJ
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Division for $4.2 Billion in Cash MT
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln RE
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion MT
Becton, Dickinson and Company entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. CI
DBS Bank Adjusts Price Target on Becton, Dickinson to $285 From $300 MT
Transcript : Becton, Dickinson and Company Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
Exclusive-Biden to put tariffs on China medical supplies - sources RE
Barclays Adjusts Price Target on Becton, Dickinson to $312 From $305, Keeps Overweight Rating MT
TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $260 From $271 MT
More news
5 years
206.21
Extreme 206.207979
249.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 31/12/08
Director of Finance/CFO 52 05/09/21
Chief Tech/Sci/R&D Officer 48 31/12/18
Members of the board TitleAgeSince
Director/Board Member 73 23/09/02
Director/Board Member 73 28/01/13
Director/Board Member 69 25/07/10
More insiders
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
228.8 USD
Average target price
278.9 USD
Spread / Average Target
+21.86%
Consensus